As drug development becomes more cloud- and vendor-driven, GxP validation has grown more complex. Traditional compliance approaches struggle to keep up with agile development, outsourced studies, and distributed data. Egnyte outlines three best practices for modern validation: leverage automation to test software, centralize regulated data across collaborators, and partner with vendors who support scalable, compliant ecosystems. By focusing on the spirit of GxP—data trust and accountability—biopharma firms can stay compliant amid rapid technology disruption.

Join for free to read